Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries

Expert Opinion on Pharmacotherapy

Volumn 20, Issue 18, 2019, Pages 2237-2255

  Godman, Brian ^a,b,c,d   Grobler, Christoffel ^e,f,g   Van De Lisle, Marianne ^h   Wale, Janney ⁱ   Barbosa, Wallace Breno ^j   Massele, Amos ^k   Opondo, Philip ^k   Petrova, Guenka ^l   Tachkov, Konstantin ^l   Sefah, Israel ^m   Abdulsalim, Suhaj ⁿ   Alrasheedy, Alian A ⁿ   Unnikrishnan, Mazhuvancherry Kesavan ^o   Garuoliene, Kristina ^p   Bamitale, Kayode ^q   Kibuule, Dan ^q   Kalemeera, Francis ^q   Fadare, Joseph ^r   Khan, Tanveer Ahmed ^s   Hussain, Shahzad ^s   Bochenek, Tomasz ^t   Kalungia, Aubrey Chichonyi ^u   Mwanza, James ^v   Martin, Antony P ^d,w   Hill, Ruaraidh ^x   Barbui, Corrado ^y   more..

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^e Elizabeth Donkin Hospital   (South Africa)

^f WALTER SISULU UNIVERSITY   (South Africa)

^g NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^h ROYAL EDINBURGH HOSPITAL   (United Kingdom)

ⁱ Independent Consumer Advocate   (Australia)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^k UNIVERSITY OF BOTSWANA   (Botswana)

^l MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^m GHANA HEALTH SERVICE   (Ghana)

ⁿ QASSIM UNIVERSITY   (Saudi Arabia)

^o National college of pharmacy   (India)

^p VILNIUS UNIVERSITY   (Lithuania)

^q UNIVERSITY OF NAMIBIA   (Namibia)

^r EKITI STATE UNIVERSITY   (Nigeria)

^s NATIONAL INSTITUTE OF HEALTH   (Pakistan)

^t JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^u UNIVERSITY OF ZAMBIA   (Zambia)

^v UNIVERSITY OF ZAMBIA   (Zambia)

^w The Innovation Centre   (United Kingdom)

^x UNIVERSITY OF LIVERPOOL   (United Kingdom)

^y UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

bipolar disorder type II; Bipolar disorders; differential diagnosis; health policies; lower and middle income countries; pharmaceuticals; treatment

Indexed keywords

NEUROLEPTIC AGENT;

BIPOLAR II DISORDER; DISEASE BURDEN; HUMAN; LOW INCOME COUNTRY; METHODOLOGY; MIDDLE INCOME COUNTRY; PREVALENCE; REVIEW; BIPOLAR DISORDER; DEVELOPING COUNTRY;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEVELOPING COUNTRIES; HUMANS;

EID: 85075539082     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2019.1684473     Document Type: Review

References (258)

1. Vigo D, Thornicroft G, Atun R., Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3(2):171–178.
2. Patel V. Mental health in low- and middle-income countries. Br Med Bull. 2007;81-82:81–96.
3. WHO. World Health Organization, Calouste Gulbenkian Foundation. Improving access to and appropriate use of medicines for mental disorders. Geneva. Available from: http://apps.who.int/iris/bitstream/10665/254794/1/9789241511421-eng.pdf?ua=1
4. Bruckner TA, Scheffler RM, Shen G, et al. The mental health workforce gap in low- and middle-income countries: a needs-based approach. Bull World Health Organ. 2011;89(3):184–194.
5. Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017;210(2):119–124.
6. Patel V, Chisholm D, Parikh R, et al. Global priorities for addressing the burden of mental, neurological, and substance use disorders. In: Patel V, Chisholm D, Dua T, et al., editors. Mental, neurological, and substance use disorders: disease control priorities. 3rd ed. Vol. 4. Washington (DC): The International Bank for Reconstruction and Development/The World Bank (c) 2016 International Bank for Reconstruction and Development/The World Bank; 2016;1–28.
7. WHO quality rights: service standards and quality in mental health care. [cited 2019 Aug 8]. Available from: https://www.who.int/mental_health/policy/quality_rights/infosheet_hrs_day.pdf?ua=1
8. Patel V, Saxena S, Lund C, et al. The Lancet Commission on global mental health and sustainable development. Lancet. 2018;392(10157):1553–1598.
9. WHO. Management of physical health conditions in adults with severe mental disorders. Available from: https://apps.who.int/iris/bitstream/handle/10665/275718/9789241550383-eng.pdf?ua=1
10. Charara R, Forouzanfar M, Naghavi M, et al. the burden of mental disorders in the eastern mediterranean region, 1990–2013. PloS One. 2017;12(1):e0169575.
11. Spagnolo J, Champagne C, Leduc N, et al. A program to further integrate mental health into primary care: lessons learned from a pilot trial in Tunisia. Jn Global Health Reports. 2019; 3 03–e2019022. [cited 2019 Oct 10]. Available from: http://www.joghr.org/Abstract/joghr-03-e2019022
12. Ouali U, Jomli R, Nefzi R, et al. Social stigma in severe mental illness in Tunisia: clinical and socio-demographic correlates. Eur Psychiatry. 2017;41:S577.
13. Federal Democratic Republic of Ethiopia Ministry of Health. NATIONAL MENTAL HEALTH STRATEGY 2012/13-2015/16. [cited 2019 Oct 9]. Available from: https://www.mhinnovation.net/sites/default/files/downloads/resource/ETHIOPIA-NATIONAL-MENTAL-HEALTH-STRATEGY-2012-1.pdf
14. Republic of Lebanon–Ministry of Public Health. Mental health and substance use–prevention, promotion, and treatment. situation analysis and strategy for lebanon 2015–2020. 2015. [cited 2019 Oct 9]. Available from: https://www.mhinnovation.net/sites/default/files/downloads/resource/MH%20strategy%20LEBANON%20ENG.pdf
15. Suleiman DE. Mental health disorders in Nigeria: a highly neglected disease. Ann Nigerian Med. 2016;10:47–48.
16. Onyemelukwe C. Stigma and mental health in Nigeria: some suggestions for law reform. J Law Policy Glob. 2016;55:63‑8.
17. Herman AA, Stein DJ, Seedat S, et al. The South African Stress and Health (SASH) study: 12-month and lifetime prevalence of common mental disorders. South Afr Med J. 2009;99(5 Pt 2):339–344.
18. El Masaiti A. One out of two people is mentally ill: gruesome reality of mental health care in Morocco. 2017. [cited 2019 Oct 8]. Available from: https://www.moroccoworldnews.com/2017/07/224718/mentally-ill-mental-health-care-morocco/
19. Hendler R, Kidia K, Machando D, et al. “We are not really marketing mental health”: mental health advocacy in Zimbabwe. PloS One. 2016;11(9):e0161860.
20. World Health Organization. Mental health atlas. Geneva; 2017. [cited 2019 Oct 8]. Available from: https://apps.who.int/iris/bitstream/handle/10665/272735/9789241514019-eng.pdf?ua=1
21. Hanna F, Barbui C, Dua T, et al. Global mental health: how are we doing? World Psychiatry. 2018;17(3):367–368.
22. Ridgwell H. Science and health. Zimbabwe tackles mental health with ‘friendship benches; 2017 [cited 2019 Oct 8]. Available from: https://www.voanews.com/a/zimbabwe-friendship-bench-mental-health-treatment/3661639.html
23. MENTAL HEALTH CARE IN GHANA. Chapter 3. National Academies of Sciences, Engineering, and Medicine. providing sustainable mental and neurological health care in Ghana and Kenya: workshop summary. Washington, DC: The National Academies Press; 2016. [cited 2019 Aug 9]. Available from: https://www.nap.edu/read/21793/chapter/4.
24. Roberts M, Asare JB, Mogan C, et al. The mental health system in Ghana; 2013. [cited 2019 Aug 8]. Available from: https://www.mhinnovation.net/sites/default/files/downloads/innovation/research/The-Mental-Health-System-in-Ghana-Report.pdf
25. Gureje O, Abdulmalik J, Kola L, et al. Integrating mental health into primary care in Nigeria: report of a demonstration project using the mental health gap action programme intervention guide. BMC Health Serv Res. 2015;15(1):242.
26. Spagnolo J, Champagne F, Leduc N, et al. Mental health knowledge, attitudes, and self-efficacy among primary care physicians working in the Greater Tunis area of Tunisia. Int J Ment Health Syst. 2018;12(1):63.
27. Seedat S, Williams DR, Herman AA, et al. Mental health service use among South Africans for mood, anxiety and substance use disorders. South Afr Med J. 2009;99(5 Pt 2):346–352.
28. WHO Mental Health Gap Action Programme. mhGAP intervention guide; 2016. [cited 2019 Apr 6]. Available from: file:///C:/Users/mail/Downloads/9789241549790-eng.pdf.
29. WHO. Mental health atlas 2011 - department of mental health and substance abuse, WHO. [cited 2019 Oct 9]. Available from: https://www.who.int/mental_health/evidence/atlas/profiles/en/#G
30. Addisu F, Wondafrash M, Chemali Z, et al. Length of stay of psychiatric admissions in a general hospital in Ethiopia: a retrospective study. Int J Ment Health Syst. 2015;9:13.
31. Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–249.
32. Ofori-Asenso R, Agyeman AA. Irrational use of medicines–a summary of key concepts. Pharmacy. 2016;4:35.
33. Oppong S, Kretchy IA, Imbeah EP, et al. Managing mental illness in Ghana: the state of commonly prescribed psychotropic medicines. Int J Ment Health Syst. 2016;10:28.
34. Acosta A, Vanegas EP, Rovira J, et al. Medicine shortages: gaps between countries and global perspectives. Front Pharmacol. 2019;10:763.
35. WHO-AIMS. Mental health systems in selected low- and middle-income countries: a WHO-AIMS cross-national analysis; 2009. [cited 2019 Mar 6]. Available from: http://www.who.int/mental_health/evidence/who_aims_report_final.pdf
36. Mendenhall E, De Silva MJ, Hanlon C, et al. Acceptability and feasibility of using non-specialist health workers to deliver mental health care: stakeholder perceptions from the PRIME district sites in Ethiopia, India, Nepal, South Africa, and Uganda. Soc Sci Med. 2014;118:33–42.
37. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Jama. 2004;291(21):2581–2590.
38. Ahmad I, Khalily MT, Hallahan B. Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort. Asian J Psychiatr. 2017;30:39–43.
39. Ezenduka C, Ubochi VN, Ogbonna BO. The utilization pattern and costs analysis of psychotropic drugs at a neuropsychiatric hospital in Nigeria. Br J Pharm Res. 2014;4(3):325–337.
40. Read UM, Doku VCK. Mental health research in Ghana: a literature review. Ghana Med J. 2012;46(2 Suppl):29–38.
41. Roberts M, Mogan C, Asare JB. An overview of Ghana’s mental health system: results from an assessment using the World Health Organization’s Assessment Instrument for Mental Health Systems (WHO-AIMS). Int J Ment Health Syst. 2014;8:16.
42. Naqvi HA, Sabzwari S, Hussain S, et al. General practitioners’ awareness and management of common psychiatric disorders: a community-based survey from Karachi, Pakistan. East Mediterr Health J. 2012;18(5):446–453.
43. Armiyau AY. A review of stigma and mental illness in Nigeria. J Clin Case Rep. 2015;5:488.
44. Kajawu L, Traditional versus contemporary medicine: mental illness in Zimbabwe; 2017. [cited 2019 Mar 10]. Available from: https://theconversation.com/traditional-versus-contemporary-medicine-mental-illness-in-zimbabwe-82764
45. Murthy SR. Lessons from the Erwadi tragedy for mental health care in India. Indian J Psychiatry. 2001;43(4):362–366.
46. Kapungwe A, Cooper S, Mwanza J, et al. Mental illness–stigma and discrimination in Zambia. Afr J Psychiatry. 2010;13(3):192–203.
47. Jombo HE, Idung AU. Stigmatising attitudes towards persons with mental illness among university students in Uyo, South-South Nigeria. IInt J Health Sci Res. 2018;8(4):24–31.
48. Chadda RK. Caring for the family caregivers of persons with mental illness. Indian J Psychiatry. 2014;56(3):221–227.
49. Kohrt BA, Rasmussen A, Kaiser BN, et al. Cultural concepts of distress and psychiatric disorders: literature review and research recommendations for global mental health epidemiology. Int J Epidemiol. 2014;43(2):365–406.
50. Mahomoodally MF. Traditional medicines in Africa: an appraisal of ten potent African medicinal plants. Evid Based Complement Alternat Med. 2013;2013:14.
51. Nortje G, Oladeji B, Gureje O, et al. Effectiveness of traditional healers in treating mental disorders: a systematic review. Lancet Psychiatry. 2016;3(2):154–170.
52. James PB, Wardle J, Steel A, et al. Traditional, complementary and alternative medicine use in Sub-Saharan Africa: a systematic review. BMJ Glob Health. 2018;3(5):e000895.
53. Becker TD, Ho-Foster AR, Poku OB, et al. “It’s when the trees blossom”: explanatory beliefs, stigma, and mental illness in the context of HIV in Botswana. Qual Health Res. 2019;29(11):1566–1580.
54. Mahmood S, Hussain S, Ur Rehman T, et al. Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. Curr Med Res Opin. 2019;35(1):51–61.
55. Centre for Mental health Law and Policy. Quality rights Gujarat; 2019. [cited 2019 Oct 8]. Available from: https://cmhlp.org/stories-of-changes/quality-rights-gujarat/
56. Rekhis M. Rights of people with mental disorders: realities and perceptions; 2015. [cited 2019 Oct 8]. Available from: https://www.who.int/mental_health/policy/quality_rights/QR_Tunisia.pdf?ua=1
57. Parwiz K, Implementation of WHO quality rights assessment in Kabul mental health hospital. [cited 2019 Oct 6]. Available from: https://www.who.int/mental_health/policy/quality_rights/QR_Afghanistan.pdf?ua=1
58. Who quality rights in mental health– Ghana, fact sheet. [cited 2019 Oct 9]. Available from: http://qualityrightsgh.com/wp-content/uploads/2019/01/FACT-SHEET.pdf
59. WHO and mhGAP. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP)–version 2.0. [cited 2019 Mar 3]. Available from: http://apps.who.int/iris/bitstream/10665/250239/1/9789241549790-eng.pdf?ua=1
60. Keynejad RC, Dua T, Barbui C, et al. WHO Mental Health Gap Action Programme (mhGAP) intervention guide: a systematic review of evidence from low and middle-income countries. Evid Based Ment Health. 2018;21(1):30–34.
61. Pathare S, Funk M, Drew Bold N, et al. Systematic evaluation of the QualityRights programme in public mental health facilities in Gujarat, India. Br J Psychiatry. 2019;1–8.
62. Funk M, Drew N. WHO QualityRights: transforming mental health services. Lancet Psychiatry. 2017;4(11):826–827.
63. Gureje O, Seedat S, Kola L, et al. Partnership for mental health development in Sub-Saharan Africa (PaM-D): a collaborative initiative for research and capacity building. Epidemiol Psychiatr Sci. 2018;28(4):389–396.
64. Acharya B, Maru D, Schwarz R, et al. Partnerships in mental healthcare service delivery in low-resource settings: developing an innovative network in rural Nepal. Global Health. 2017;13(1):2.
65. Nartey AK, Badu E, Agyei-Baffour P, et al. The predictors of treatment pathways to mental health services among consumers in Ghana. Perspect Psychiatr Care. 2019;55(2):300–310.
66. Jin H, McCrone P. Cost-of-illness studies for bipolar disorder: systematic review of international studies. PharmacoEconomics. 2015;33(4):341–353.
67. Bobo WV, Diagnosis T. Management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc. 2017;92(10):1532–1551.
68. Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–11.
69. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
70. National Collaborating Centre for Mental Health Bipolar Disorder: the NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. NICE (National Institute for Health and Care Excellence); 2014.
71. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
72. Severus E, Bauer M. Diagnosing bipolar disorders in DSM-5. Int J Bipolar Disord. 2013;1:14.
73. Angst J, Rossler W, Ajdacic-Gross V, et al. Differences between unipolar mania and bipolar-I disorder: evidence from nine epidemiological studies. Bipolar Disord. 2019;21(5):437–448.
74. Angst J, Gamma A, Bowden CL, et al. Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the bridge study: validity and comorbidity. Eur Arch Psychiatry Clin Neurosci. 2013;263(8):663–673.
75. Vinberg M, Mikkelsen RL, Kirkegaard T, et al. Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: a naturalistic study. J Affect Disord. 2017;208:521–527.
76. Chrobak AA, Siwek M, Dudek D, et al. Content overlap analysis of 64 (hypo)mania symptoms among seven common rating scales. Int J Methods Psychiatr Res. 2018;27(3):e1737.
77. Verdolini N, Hidalgo-Mazzei D, Murru A, et al. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand. 2018;138(3):196–222.
78. Angst J, Merikangas KR, Cui L, et al. Bipolar spectrum in major depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2018;268(8):741–748.
79. Parker G, Fletcher K. Differentiating bipolar I and II disorders and the likely contribution of DSM-5 classification to their cleavage. J Affect Disord. 2014;152-154:57–64.
80. Betzler F, Stover LA, Sterzer P, et al. Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017;21(4):244–258.
81. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572.
82. Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the global burden of disease study 2013. Bipolar Disord. 2016;18(5):440–450.
83. Clemente AS, Diniz BS, Nicolato R, et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Rev Bras Psiquiatr. 2015;37(2):155–161.
84. Vassos E, Agerbo E, Mors O, et al. Urban-rural differences in incidence rates of psychiatric disorders in Denmark. Br J Psychiatry. 2016;208(5):435–440.
85. Carta MG, Moro MF, Piras M, et al. Megacities, migration and an evolutionary approach to bipolar disorder: a study of Sardinian immigrants in Latin America. Rev Bras Psiquiatr. 2019.
86. Gruebner O, Rapp MA, Adli M, et al. Cities and mental health. Dtsch Arztebl Int. 2017;114(8):121–127.
87. Heinz A, Deserno L, Reininghaus U. Urbanicity, social adversity and psychosis. World Psychiatry. 2013;12(3):187–197.
88. Khazaei S, Armanmehr V, Nematollahi S, et al. Suicide rate in relation to the human development index and other health related factors: a global ecological study from 91 countries. J Epidemiol Glob Health. 2017;7(2):131–134.
89. Dell’Osso B, Grancini B, Vismara M, et al. Age at onset in patients with bipolar I and II disorder: a comparison of large sample studies. J Affect Disord. 2016;201:57–63.
90. Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59(Suppl 1):S51–s66.
91. Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the National epidemiologic survey on alcohol and related conditions–III. J Psychiatr Res. 2017;84:310–317.
92. Azale G, Araya T, Melaku E. More than half of bipolar patients attending Emanuel mental specialized hospital has poor quality of life, Emanuel mental specialized hospital, Ethiopia: facility-based cross-sectional study design. J Psychiatry. 2018;21:454.
93. Hirschfeld RM. Screening for bipolar disorder. Am J Manag Care. 2007;13(7 Suppl):S164–9.
94. Kronfol Z, Zakaria Khalil M, Kumar P, et al. Bipolar disorders in the Arab world: a critical review. Ann N Y Acad Sci. 2015;1345:59–66.
95. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
96. Samalin L, Vieta E, Okasha TA, et al. Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions. Sci Rep. 2016;6:25920.
97. Esan O, Esan A. Epidemiology and burden of bipolar disorder in Africa: a systematic review of data from Africa. Soc Psychiatry Psychiatr Epidemiol. 2016;51(1):93–100.
98. Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol. 2014;43(2):476–493.
99. The South African Depression and Anxiety Group (SADAG). 3-4% of South Africans have bipolar disorder. [cited 2019 Sept 8]. Available from: http://www.sadag.org/index.php?option=com_content&view=article&id=47:3-4-of-south-africans-have-bipolar-disorder&catid=57&Itemid=149
100. Bouchra O, Maria S, Abderazak O. Screening of the unrecognised bipolar disorders among outpatients with recurrent depressive disorder: a cross-sectional study in psychiatric hospital in Morocco. Pan Afr Med J. 2017;27:247.
101. Derbel C, Feki R, Ben Nasr S, et al. The late-onset bipolar disorder: a comparative study. Eur Psychiatry. 2017;41S:S106–S169 (EW0024).
102. Haycox A. Why cancer? PharmacoEconomics. 2016;34(7):625–627.
103. Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
104. Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543.
105. Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791–794.
106. Williams MD, Shah ND, Wagie AE, et al. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatric Serv. 2011;62(9):1073–1078.
107. Kleine-Budde K, Touil E, Moock J, et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16(4):337–353.
108. Addo R, Agyemang SA, Tozan Y, et al. Economic burden of caregiving for persons with severe mental illness in sub-Saharan Africa: a systematic review. PloS One. 2018;13(8):e0199830.
109. Sharma P, Das SK, Deshpande SN. An estimate of the monthly cost of two major mental disorders in an Indian metropolis. Indian J Psychiatry. 2006;48(3):143–148.
110. Eddahby S, Kadri N, Moussaoui D. Fasting during Ramadan is associated with a higher recurrence rate in patients with bipolar disorder. World Psychiatry. 2014;13(1):97.
111. Fajutrao L, Locklear J, Priaulx J, et al. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Mental Health. 2009;5:3.
112. Charlson FJ, Baxter AJ, Dua T, et al. Excess mortality from mental, neurological, and substance use disorders in the global burden of disease study 2010. In: Patel V, Chisholm D, Dua T, et al., editors. Mental, neurological, and substance use disorders: disease control priorities. 3rd ed. Vol. 4. Washington (DC): The International Bank for Reconstruction and Development/The World Bank (c) 2016 International Bank for Reconstruction and Development/The World Bank; 2016;41–66.
113. WHO. Suicide - key facts; 2019. [cited 2019 Oct 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/suicide
114. Schaffer A, Isometsa ET, Tondo L, et al. International society for bipolar disorders task force on suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015;17(1):1–16.
115. Outhoff K. Bipolar disorder: an update. S Afr Family Pract. 2017;59(4):6–10.
116. Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R, et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom. 2009;78(5):285–297.
117. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398–405.
118. Kebede D, Fekadu A, Shibre KT, et al. The 11-year functional outcome of bipolar and major depressive disorders in Butajira, Ethiopia. Neurol Psychiatry Brain Res. 2019;32:68–76.
119. Marrag I, Hajji K, Hadj Ammar M, et al. [Bipolar disorder and quality of life: a cross-sectional study including 104 Tunisian patients]. L’Encephale. 2015;41(4):355–361.
120. O’Donnell LA, Ellis AJ, Van de Loo MM, et al. Mood instability as a predictor of clinical and functional outcomes in adolescents with bipolar I and bipolar II disorder. J Affect Disord. 2018;236:199–206.
121. Faurholt-Jepsen M, Frost M, Busk J, et al. Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. Int J Bipolar Disord. 2019;7(1):5.
122. Malhi GS, Outhred T, Morris G, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Med J Aust. 2018;208(5):219–225.
123. Reddy YJ, Jhanwar V, Nagpal R, et al. Prescribing practices of Indian psychiatrists in the treatment of bipolar disorder. Aust N Z J Psychiatry. 2019;53(5):458–469.
124. Sahoo S, Grover S, Malhotra R, et al. Internalized stigma experienced by patients with first-episode depression: a study from a tertiary care center. Indian J Soc Psychiatry. 2018;34:21–29.
125. Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.
126. Sajatovic M, DiBiasi F, Legacy SN. Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review. Neuropsychiatr Dis Treat. 2017;13:2285–2296.
127. Ethiopia Federal Ministry of Health, WHO. mhGAP in Ethiopia: proof of ConCEPt 2013. [cited 2019 Oct 10]. Available from: https://www.mhinnovation.net/sites/default/files/downloads/resource/mhGap%20in%20Ethiopia-%20Proof%20of%20Concept.pdf
128. Haque M, McKimm J, Godman B, et al. Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. Expert Rev Anticancer Ther. 2019;19(1):81–92.
129. Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
130. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
131. Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
132. Godman B, Malmstrom RE, Diogene E, et al. Dabigatran–a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014;5:109.
133. Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.
134. Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol. 2015;116(2):146–157.
135. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141.
136. Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PloS One. 2017;12(12):e0190147.
137. Bochenek T, Abilova V, Alkan A, et al. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian Countries. Front Pharmacol. 2017;8:942.
138. World Bank. World bank country and lending groups–country classifications; 2018. [cited 2019 Mar 3]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
139. Ibrahim AW, Pindar SK, Yerima MM, et al. Medication-related factors of non adherence among patients with schizophrenia and bipolar disorder: outcome of a cross-sectional survey in Maiduguri, North-eastern Nigeria. J Neurosci Behav Health. 2015;7(5):31–39.
140. Dodd S, Williams LJ, Jacka FN, et al. Reliability of the mood disorder questionnaire: comparison with the structured clinical interview for the DSM-IV-TR in a population sample. Aust N Z J Psychiatry. 2009;43(6):526–530.
141. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27.
142. Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017;217:266–280.
143. Rybakowski JK. Challenging the negative perception of lithium and optimizing its long-term administration. Front Mol Neurosci. 2018;11:349.
144. Grande I, Vieta E. Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? CNS Drugs. 2015;29(3):221–227.
145. Commodore-Mensah Y, Samuel LJ, Dennison-Himmelfarb CR, et al. Hypertension and overweight/obesity in Ghanaians and Nigerians living in West Africa and industrialized countries: a systematic review. J Hypertens. 2014;32(3):464–472.
146. Cois A, Day C. Obesity trends and risk factors in the South African adult population. BMC Obes. 2015;2:42.
147. World Health Organization–Noncommunicable Diseases (NCD) Country Profiles. Botswana; 2018. [cited 2019 Mar 4]. Available from: https://www.who.int/nmh/countries/bwa_en.pdf?ua=1
148. Adekanmbi VT, Uthman OA, Erqou S, et al. Epidemiology of prediabetes and diabetes in Namibia, Africa: A multilevel analysis. J Diabetes. 2019;11(2):161–172.
149. WHO. World Health Organisation, diabetes fact sheet July 2016. [cited 2019 Mar 4]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
150. IDF diabetes atlas 8th edition 2017. [cited 2019 Mar 4]. Available from: http://www.diabetesatlas.org/resources/2017-atlas.html
151. Ofori-Asenso R, Agyeman AA, Laar A, et al. Overweight and obesity epidemic in Ghana–a systematic review and meta-analysis. BMC Public Health. 2016;16(1):1239.
152. Werfalli M, Engel ME, Musekiwa A, et al. The prevalence of type 2 diabetes among older people in Africa: a systematic review. Lancet Diabetes Endocrinol. 2016;4(1):72–84.
153. Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241.
154. Wang H, Wolock TM, Carter A, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the global burden of disease study 2015. Lancet HIV. 2016;3(8):e361–87.
155. Gaida R, Truter I, Grobler C, et al. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Rev Anti Infect Ther. 2016;14(4):377–388.
156. Boxler D. Psychiatric times. FDA approves vraylar (Cariprazine) for bipolar depression; 2019. [cited 2019 Aug 8]. Available from: https://www.psychiatrictimes.com/bipolar-disorder/fda-approves-vraylar-cariprazine-bipolar-depression
157. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–1262.
158. Fela-Thomas AL, Olotu OS, Esan O. Risk of manic switch with antidepressants use in patients with bipolar disorder in a Nigerian neuropsychiatric hospital. S Afr J Psychiatr. 2018;24:1215.
159. Valenti M, Pacchiarotti I, Bonnin CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry. 2012;73(2):e271–6.
160. Peters EM, Bowen R, Balbuena L. Melancholic symptoms in bipolar II depression and responsiveness to lamotrigine in an exploratory pilot study. J Clin Psychopharmacol. 2018;38(5):509–512.
161. Faurholt-Jepsen M. Electronic monitoring in bipolar disorder. Dan Med J. 2018;65:3.
162. Jaracz J, Rudnicka ET, Bierejszyk M, et al. The pattern of pharmacological treatment of bipolar patients discharged from psychiatric units in Poland. Pharmacol Rep. 2018;70(4):694–698.
163. Patton DE, Hughes CM, Cadogan CA, et al. Theory-based interventions to improve medication adherence in older adults prescribed polypharmacy: a systematic review. Drugs Aging. 2017;34(2):97–113.
164. Carmona-Huerta J, Castiello-de Obeso S, Ramirez-Palomino J, et al. Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC Psychiatry. 2019;19(1):78.
165. Ulley J, Harrop D, Ali A, et al. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr. 2019;19(1):15.
166. Al-Taweel DM, Alsuwaidan M. A medication assessment tool to evaluate prescribers’ adherence to evidence-based guidelines in bipolar disorder. Int J Clin Pharm. 2017;39(4):897–905.
167. Niaz Q, Godman B, Massele A, et al. Validity of World Health Organisation prescribing indicators in Namibia’s primary healthcare: findings and implications. Int J Qual Health Care. 2019;31(5):338–345.
168. Fekadu A, Hanlon C, Thornicroft G, et al. Care for bipolar disorder in LMICs needs evidence from local settings. Lancet Psychiatry. 2015;2(9):772–773.
169. Republic of Ghana. Ministry of Health (GNDP) Standard Treatment Guidelines. 7th ed; 2017. [cited 2019 Mar 2]. Available from: https://www.dropbox.com/s/p1218b0s2tv60fs/STG%20GHANA%202017.pdf?dl=0
170. Trivedi JK, Sareen H, Yadav VS, et al. Prescription pattern of mood stabilizers for bipolar disorder at a tertiary health care centre in north India. Indian J Psychiatry. 2013;55(2):131–134.
171. Onyeama M, Agomoh A, Jombo E. Bipolar disorder in Enugu, South East Nigeria: demographic and diagnostic characteristics of patients. Psychiatr Danub. 2010;22(Suppl 1):S152–7.
172. Ashara HH. Mania and hypomania bipolar disorder. Mentally Aware Nigeria Initiative (MANI); 2018. [cited 2019 Mar 4]. Available from: https://www.mentallyaware.org/mania-and-hypomania-in-bipolar-disorder/
173. Obiora N. What is bipolar disorder, how to recognise it and treatment options. Pulse; 2018. [cited 2019 Mar 4]. Available from: https://www.pulse.ng/lifestyle/beauty-health/metal-health-awareness-what-is-bipolar-disorder-how-to-recognise-it-and-treatment/94lvnsk
174. Jombo HE, Idung AU. Medication related factors of adherence and attitude to medication among outpatients with bipolar disorder in Uyo, South-South Nigeria. Int Neuropsychiatr Dis J. 2017;1–10.
175. Kehinde OA, Anyika EN, Abah I. Drug utilization patterns of antidepressants in federal neuro-psychiatric hospital Lagos, Nigeria. J Hosp Administration. 2017;6:5.
176. Adeponle AB, Obembe AO, Adeyemi SO, et al. Polypharmacy in psychiatric out-patient practice in northern Nigeria. Afr J Psychiatry. 2007;10(4):215–218.
177. Fadare JO, Lawal MA, Elegbede AO, et al. Medication adherence and patients satisfaction among psychiatric outpatients in a rural nigerian tertiary healthcare facility. J Psychiatry. 2014;17:125.
178. Khalily M. Mental health problems in Pakistani society as a consequence of violence and trauma: a case for better integration of care. Int J Integr Care. 2011;11:1–7.
179. Altaf A, Khan M, Shah SR, et al. Sociodemographic pattern of depression in urban settlement of Karachi, Pakistan. J Clin Diagn Res. 2015;9(6):VC09–VC13.
180. Gadit AA. Mental health in Pakistan: where do we stand? J Pak Med Assoc. 2006;56(5):198–199.
181. Husain MI, Chaudhry IB, Rahman RR, et al. Pilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan. Int J Bipolar Disord. 2017;5(1):3.
182. Ministy of Health Tunisia. La Stratégie nationale de promotion de la santé mentale. Ministry of Health; 2013. [cited 2019 Oct 6]. Available from: https://www.mindbank.info/item/6277
183. Spagnolo J, Champagne F, Leduc N, et al. Building system capacity for the integration of mental health at the level of primary care in Tunisia: a study protocol in global mental health. BMC Health Serv Res. 2017;17(1):38.
184. Ministry of Health. Essential medicine list. Government of Zambia; 2013. [cited 2019 Mar 18]. Available from: https://www.who.int/selection_medicines/country_lists/Zambia_EML_2013.pdf?ua=1
185. Ministry of Health. Standard treatment guidelines, essential medicine list and essential laboratory supplies list for Zambia. Government of Zambia; 2013. [cited 2019 Mar 18]. Available from: http://www.moh.gov.zm/docs/final_standard_treatment_guidelines_booklet_04.pdf
186. Mwanza J, Paul R, Ncheka JM, et al. Appropriateness of antipsychotic drugs prescribed for first episode psychosis by clinicians at Chainama Hills college hospital in Lusaka. Health Press Zambia Bull. 2017;1(4):20–28.
187. Botswana Essential Drug List. Second; 2012. [cited 2019 Mar 18]. Available from: http://apps.who.int/medicinedocs/documents/s19479en/s19479en.pdf
188. Brasil. Ministério da Saúde. Portaria nº 315, de 30 de março de 2016. Aprova o Protocolo Clínico e Diretrizes Terapêuticas do Transtorno Afetivo Bipolar do tipo I. [cited 2019 Mar 6]. Available from: http://conitec.gov.br/images/Protocolos/PCDT_TranstornoAfetivoBipolar_TipoI.pdf
189. Brasil. Ministério da Saúde. Lei nº 10.216, de 6 de abril de 2001. Dispõe sobre a proteção e os direitos das pessoas portadoras de transtornos mentais e redireciona o modelo assistencial em saúde mental. [cited 2019 Mar 6]. Available from: http://www.planalto.gov.br/ccivil_03/leis/leis_2001/l10216.htm
190. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. DAPE. Reforma psiquiátrica e política de saúde mental no Brasil. Brasília, novembro de 2005. [cited 2019 Mar 6]. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/Relatorio15_anos_Caracas.pdf
191. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais: RENAME 2018. Brasília: Ministério da Saúde; 2018; 218 p. [cited 2019 Mar 6]. Available from: http://conitec.gov.br/images/Artigos_Publicacoes/Rename/Rename_2018_Novembro.pdf
192. Caires de Souza AL, de Assis Acurcio F, Guerra Junior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.
193. Ignatova D, Kamusheva M, Petrova G, et al. Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. Biotechnol Biotechnol Equip. 2019;1(11):1–10.
194. Ignatova D, Kamusheva M, Petrova G, et al. Burden of informal care for individuals with schizophrenia and affective disorders prior to hospital admission. Eur J Psych. 2018;12:24.
195. Namibian Treatment Guidelines. Ministry of health and social services. 1st edition 2011. Government of Republic of Namibia. [cited 2019 Mar 6]. Available from: http://apps.who.int/medicinedocs/documents/s19260en/s19260en.pdf
196. Republic of Namibia. Ministry of Health and Social Services (MoHSS). National Policy for Mental Health. 2005.
197. Janse van Rensburg ABR. Contributions from the South African Society of Psychiatrists (SASOP) to the National mental health action plan. S Afr J Psych. 2013;19(4):205–212.
198. Department of Health Republic of South Africa. National Mental Health Policy Framework And Strategic Plan–2013-2020; 2012. [cited 2019 Mar 6]. Available from: https://www.health-e.org.za/wp-content/uploads/2014/10/National-Mental-Health-Policy-Framework-and-Strategic-Plan-2013-2020.pdf
199. The South African Depression and Anxiety group. Bipolar disorder treatment and referral guide. [cited 2019 Mar 6]. Available from: http://www.sadag.org/index.php?option=com_content&view=article&id=1838&Itemid=147
200. National Department of Health Republic of South Africa. Standard treatment guidelines and essential medicines list for South Africa–third edition 2012 [cited 2019 Mar 6]. Available from: https://apps.who.int/medicinedocs/documents/s21732en/s21732en.pdf
201. Seedat S, Emsley R. The South African Society of Psychiatrists (SASOP) treatment guidelines for psychiatric disorders 2013. S Afr J Psych. 2013;19(3):128–199.
202. Kumar A. Mental health services in rural India: challenges and prospects. Health. 2011;3(12):757–761.
203. Singh OP. Insurance for mental illness: government schemes must show the way. Indian J Psychiatry. 2019;61:113–114.
204. Sarkar S, Mathan K, Sakey S, et al. Cost-of-treatment of clinically stable severe mental illnesses in India. Indian J Soc Psychiatry. 2017;33:262–268.
205. Modi PM. India to increase public health spending to 2.5% of GDP. 2018. [cited 2019 Mar 10]. Available from: https://economictimes.indiatimes.com/news/economy/policy/india-to-increase-public-health-spending-to-2-5-of-gdp-pm-modi/articleshow/67055735.cms
206. Economic Times Healthworld. Number of psychiatrists in India is disappointing in terms of population: Dr. Kersi Chavda. 2017. [cited 2019 Mar 10]. Avialable from: https://health.economictimes.indiatimes.com/news/industry/number-of-psychiatrists-in-india-is-disappointing-in-terms-of-population-dr-kersi-chavda/57197480
207. Sharma A, Ladd E, Unnikrishnan MK. Healthcare inequity and physician scarcity empowering non-physician healthcare. Econ Political Weekly. 2013;48(13):112–117.
208. Unnikrishnan MK, Sharma A. Misplaced reverence for super-specialists has led to lopsided public health priorities in India; 2018. [cited 2019 Mar 7]. Avaialable from: https://www.epw.in/engage/article/misplaced-reverence-for-super-specialists-has-led-to-lop-sided-public-health-priorities-in-india
209. Jack-Ide IO, Uys L. Barriers to mental health services utilization in the Niger Delta region of Nigeria: service users’ perspectives. Pan Afr Med J. 2013;14:159.
210. Agboola AA, Esan OT, Afolabi OT, et al. Economic burden of the therapeutic management of mental illnesses and its effect on household purchasing power. PloS One. 2018;13(9):e0202396.
211. Abdulmalik J, Kola L, Gureje O. Mental health system governance in Nigeria: challenges, opportunities and strategies for improvement. Global Mental Health. 2016;3:e9.
212. WHO. World Health Organization–AIMS Report on mental health system in Pakistan; 2009. [cited 2019 Mar 6]. Available from: http://www.who.int/mental_health/pakistan_who_aims_report.pdf
213. Riaz H, Godman B, Hussain S, et al. Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future. JPHSR. 2015;6:111–121.
214. Mwape L, Mweemba P, Kasonde J. Strengthening the health system to enhance mental health in Zambia: a policy brief. Int J Technol Assess Health Care. 2012;28(3):294–300.
215. Mwape L, Mweemba P. Strengthening the health system for mental health in Zambia (policy brief). Lusaka (Zambia): The Zambia Forum for Health Research; 2010. [cited 2019 Mar 7]. Available from: https://www.who.int/evidence/sure/MentalhealthZambia.pdf
216. Olashore AA, Frank-Hatitchki B, Ogunwobi O. Diagnostic profiles and predictors of treatment outcome among children and adolescents attending a national psychiatric hospital in Botswana. Child Adolesc Psychiatry Ment Health. 2017;11:8.
217. Opondo PR, Ho-Foster AR, Ayugi J, et al. HIV prevalence among hospitalized patients at the main psychiatric referral hospital in Botswana. AIDS Behav. 2018;22(5):1503–1516.
218. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663–1671.
219. Organização Pan-Americana da Saúde. Relatório 30 anos de SUS. Que SUS para 2030? Brasília–DF; 2018. [cited 2019 Mar 6]. Available from: https://apsredes.org/wp-content/uploads/2018/10/Serie-30-anos-001-SINTESE.pdf
220. Petersen I, Fairall L, Bhana A, et al. Integrating mental health into chronic care in South Africa: the development of a district mental healthcare plan. Br J Psychiatry. 2016;208(56):s29–s39.
221. Schierenbeck I, Johansson P, Andersson L, et al. Barriers to accessing and receiving mental health care in Eastern Cape, South Africa. Health Hum Rights. 2013;15(2):110–123.
222. Department of Health South Africa. Human resources for health South Africa. Human resources strategy for the health sector: 2012/13–2016/17; 2012. [cited 2019 Mar 8]. Available from: https://www.gov.za/sites/default/files/gcis_document/201409/hrhstrategy0.pdf
223. De Kock JH, Pillay BJ. A situation analysis of psychiatrists in South Africa’s rural primary healthcare settings. Afr J Prim Health Care Fam Med. 2017;9(1):e1–e6.
224. Maconick L, Jenkins LS, Fisher H, et al. Mental health in primary care: integration through in-service training in a South African rural clinic. Afr J Prim Health Care Fam Med. 2018;10(1):e1–e7.
225. Lund C, Petersen I, Kleintjes S, et al. Mental health services in South Africa: taking stock. Afr J Psychiatry. 2012;15(6):402–405.
226. Makgoba MW. HEALTH OMBUD: republic of South Africa. THE REPORT INTO THE ‘CIRCUMSTANCES SURROUNDING THE DEATHS OF MENTALLY ILL PATIENTS: GAUTENG PROVINCE’ - NO GUNS: 94+ SILENT DEATHS AND STILL COUNTING; 2017. [cited 2019 Mar 6]. Available from: https://www.sahrc.org.za/home/21/files/Esidimeni%20full%20report.pdf
227. WHO. World Health Organization model list of essential Medicines; 2019. [cited 2019 Aug 3]. Available from: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=21stList201
228. Fils-Aime JR, Grelotti DJ, Therosme T, et al. A mobile clinic approach to the delivery of community-based mental health services in rural Haiti. PloS One. 2018;13(6):e0199313.
229. O’Neill J. Securing new drugs for future generations: the pipeline of antibiotics. The review of antimicrobial resistance. [cited 2019 Mar 5]. Available from: https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
230. Jinks T, Lee N, Sharland M, et al. A time for action: antimicrobial resistance needs global response. Bull World Health Organ. 2016;94(8):558–a.
231. WHO. Global action plan on antimicrobial resistance. [cited 2019 Mar 5]. Available from: http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/
232. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PloS One. 2017;12(12):e0189621.
233. Boucher HW, Bakken JS, Murray BE. The United Nations and the urgent need for coordinated global action in the fight against antimicrobial resistance. Ann Intern Med. 2016;165(11):812–813.
234. Ocan M, Obuku EA, Bwanga F, et al. Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. BMC Public Health. 2015;15:742.
235. Kibuule D, Kagoya HR, Godman B. Antibiotic use in acute respiratory infections in under-fives in Uganda: findings and implications. Expert Rev Anti Infect Ther. 2016;14(9):863–872.
236. Sakeena MHF, Bennett AA, McLachlan AJ. Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: a systematic review. Int J Antimicrob Agents. 2018;52(6):771–782.
237. WHO. A global brief on hypertension–silent killer, global public health crisis. World Health Day 2013. [cited 2019 Mar 3]. Available from: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1
238. Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016;11(3):299–305.
239. IDF. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2015 and 2040. Available from: http://www.diabetesatlas.org/
240. Mbui JM, Oluka MN, Guantai EM, et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol. 2017;10(11):1263–1271.
241. Republic of South Africa. Essential drugs programme. Primary healthcare standard treatment guideline and essential medicine list. 6th ed. National Department of Health; 2018. [cited 2019 Aug 6]. Available from: file:///C:/Users/mail/Downloads/primaryhealthcarelevel_2018_signed%20(1).pdf.
242. Federal Democratic Republic of Ethiopia Ministry of Health. NATIONAL MENTAL HEALTH STRATEGY 2012/13-2015/16. 201. [cited 2019 Aug 7]. Available from: https://www.mhinnovation.net/sites/default/files/downloads/innovation/reports/ETHIOPIA-NATIONAL-MENTAL-HEALTH-STRATEGY-2012-1.pdf
243. New 50 million pound cancer fund already intellectually bankrupt. Lancet. 2010;376(9739):389.
244. Godman B, Wild C, Haycox A. Patent expiry and costs for anti-cancer medicines for clinical use. GaBI J. 2017;6(3):105–106.
245. Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’–a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224–233.
246. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69(Suppl 1):73–78.
247. Eriksen J, Gustafsson LL, Ateva K, et al. High adherence to the ‘Wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7(4):e014345.
248. Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther. 2017;31(5–6):565–578.
249. Rampamba EM, Meyer JC, Helberg E, et al. Knowledge of hypertension and its management among hypertensive patients on chronic medicines at primary health care public sector facilities in South Africa; findings and implications. Expert Rev Cardiovasc Ther. 2017;15(8):639–647.
250. Rampamba EM, Meyer JC, Godman B, et al. Evaluation of antihypertensive adherence and its determinants at primary healthcare facilities in rural South Africa. J Comp Eff Res. 2018;7(7):661–672.
251. Rampamba E, Meyer JC, Helberg EA, et al. Empowering hypertensive patients on chronic medicines at primary health care facilities in South Africa with knowledge to improve disease management (In Press Journal of Research in Pharmacy Practice).
252. Meyer JC, Schellack N, Stokes J, et al. Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study. Front Pharmacol. 2017;8:751.
253. Sandoz - A Novartis Division. Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases; 2015. Available from: https://www.sandoz.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment
254. Fadare JO, Adeoti AO, Desalu OO, et al. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):639–650.
255. Cameron A, Mantel-Teeuwisse AK, Leufkens HG, et al. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673.
256. Khan B, Godman B, Babar A, et al. Assessment of active pharmaceutical ingredients in the registration procedures in Pakistan: implications for the future. GaBI J. 2016;5(4):156–163.
257. McKay R, Mah A, Law MR, et al. Systematic review of factors associated with antibiotic prescribing for respiratory tract infections. Antimicrob Agents Chemother. 2016;60(7):4106–4118.
258. Cross EL, Tolfree R, Kipping R. Systematic review of public-targeted communication interventions to improve antibiotic use. J Antimicrob Chemother. 2017;72(4):975–987.